Pembrolizumab before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how well a treatment combining pembrolizumab (an immunotherapy drug) with chemotherapy works before surgery for triple-negative breast cancer. It aims to understand the benefits and side effects in real-world patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have been diagnosed with triple-negative breast cancer.
- Your cancer is at stage II or III.
- You started treatment with pembrolizumab plus chemotherapy before surgery after July 2022.
- You have not had other cancers recently (except for some that were cured more than 5 years ago).
- You have not had previous breast cancer that came back in the same area.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new drug called QL1706 (an immunotherapy that helps your immune system fight cancer) combined with standard chemotherapy before surgery. The goal is to see if this combination can shrink or eliminate the tumor more effectively in early-stage triple-negative breast cancer, potentially improving your long-term outcome.
This trial tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy, before surgery, can improve treatment for early triple-negative breast cancer. It compares two chemotherapy approaches—one with anthracyclines and one without—to see which works better when combined with toripalimab.
This trial tests two different sequences of chemotherapy combined with pembrolizumab (an immunotherapy drug) given before surgery for high-risk triple-negative breast cancer. The goal is to see which sequence works better at shrinking or eliminating the tumor.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
This trial tests if giving more of the immunotherapy drug pembrolizumab (Keytruda) after surgery helps people with early-stage triple-negative breast cancer that did not completely disappear with the initial chemotherapy plus immunotherapy. This is for patients who still have some cancer left after surgery, to reduce the chance of it coming back.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy before surgery improves immune and clinical responses in people with early-stage triple-negative breast cancer. You may benefit by getting a potentially more effective treatment plan, while the study team closely monitors your response.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.